Plain-English translation of NCT07873450 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
is a new radioactive medication being tested to treat advanced cancers that have high levels of a protein called c-MET. This trial will first find the safest and most effective dose of the medication, then test whether it actually works against several types of cancer. The medication works by targeting cancer cells that display this specific protein marker.
Many patients with advanced cancers run out of treatment options after standard therapies stop working or become too toxic. This medication represents a new approach—using targeted radioactive therapy—that may help patients whose cancers have this specific protein marker.
You likely qualify if…
You likely don't qualify if…
The trial happens in phases. First, small groups of patients receive increasing doses of the medication to find the safest amount. Next, researchers compare two different dosing schedules to pick the best one. Finally, larger groups of patients with different cancer types receive the selected dose to see if the treatment actually works. Throughout the trial, you'll have regular clinic visits for blood tests, imaging scans, and physical exams to monitor your cancer and any side effects from the medication.
AI-generated summary from trial data · Nov 3, 2026 · Not medical advice
United States
Australia